But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
With a slashed valuation the newly listed biotech heads for phase 3.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
An actinium-based backup and Werner helicase inhibitor are notable absences.
